Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adenoid Cystic Carcinoma: early-phase trial registry
9 of 17 indexed Adenoid Cystic Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 9 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Adenoid Cystic Carcinoma: 17 US clinical trials tracked, 9 recruiting.
Adenoid Cystic Carcinoma is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition adenoid-cystic-carcinoma
OPEN 9 | RECR 53% | LATE 0 | EARLY 16 | RANK #1004 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Advanced Hepatocellular Carcinoma (53% recruiting · 17 trials)
Adenoid Cystic Carcinoma lists 9 open slots (53% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adenoid Cystic Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adenoid Cystic Carcinoma is recruiting above its size-band peers.
9 of 17 indexed trials (52.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Adenoid Cystic Carcinoma research.
Memorial Sloan Kettering Cancer Center accounts for 5 of 17 trials (29.4%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Adenoid Cystic Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 38 among the 17 trials that report a genuine target (sentinel values excluded). 12 of those (70.6%) plan for fewer than 100 participants.
-
Adenoid Cystic Carcinoma research is mostly interventional.
17 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
A Study of XMT-1660 in Participants With Solid Tumors
Mersana Therapeutics
NCT05377996
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology
NCT03556228
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Rgenta Therapeutics
NCT06462183
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Remix Therapeutics
NCT06118086
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility
NCT06805825
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Glenn J. Hanna
NCT06805617
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
NCT06891560
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Glenn J. Hanna
NCT05774899
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
Dana-Farber Cancer Institute
NCT04883671
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
NCT02834013
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Memorial Sloan Kettering Cancer Center
NCT04209660
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
NCT04895735
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Glenn J. Hanna
NCT05010629
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
NCT02780310
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
M.D. Anderson Cancer Center
NCT04973683
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
NCT02098538
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
NCT01558661
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Adenoid Cystic Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adenoid Cystic Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adenoid Cystic Carcinoma page
17 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Adenoid Cystic Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Adenoid Cystic Carcinoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenoid Cystic Carcinoma condition card totals 17 registered trials; most-linked intervention Lenvatinib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.